Search results for "autosomal dominant"

showing 10 items of 45 documents

Systemic redox biomarkers and their relationship to prognostic risk markers in autosomal dominant polycystic kidney disease and IgA nephropathy.

2017

Abstract Background Oxidative stress is evident from an early stage in chronic kidney disease (CKD). Therefore, we investigated redox biomarkers in polycystic kidney disease (ADPKD) and IgA nephropathy (IGAN). Methods This is a case-control study with three groups: ADPKD (n = 54), IGAN (n = 58) and healthy controls (n = 86). The major plasma aminothiols with their redox species were examined: homocysteine (Hcy), cysteinglycine (CG), cysteine (Cys) and glutathione (GSH). The redox ratio was the ratio of reduced free and oxidized aminothiols in plasma. We investigated malonedialdehyde (MDA) and advanced oxidation protein products (AOPP), and ten single nucleotide polymorphisms of antioxidant …

0301 basic medicineAdultMaleRiskmedicine.medical_specialtyHomocysteineClinical Biochemistry030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseurologic and male genital diseasesmedicine.disease_causePolymorphism Single NucleotideNephropathy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinePolycystic kidney diseaseMedicineHumansHomocysteineGenetic Association StudiesProteinuriabusiness.industrySuperoxide DismutaseGlomerulonephritis IGAGeneral MedicineDipeptidesMiddle Agedmedicine.diseasePolycystic Kidney Autosomal DominantPrognosisOxidative Stress030104 developmental biologyEndocrinologychemistryAdvanced Oxidation Protein ProductsCase-Control StudiesDisease ProgressionFemaleGene polymorphismLipid Peroxidationmedicine.symptombusinessOxidoreductasesOxidation-ReductionOxidative stressBiomarkersKidney diseaseClinical biochemistry
researchProduct

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

2017

Abstract Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major…

0301 basic medicineApolipoprotein ECandidate geneSettore MED/09 - Medicina InternaDatabases FactualApolipoprotein BDNA Mutational AnalysisFamilial hypercholesterolemia030204 cardiovascular system & hematologyCompound heterozygosityPCSK90302 clinical medicineRisk FactorsReceptorsGeneticsHomozygoteAutosomal dominant traitPathogenic variantsGeneral MedicinePrognosisAPOB; Familial hypercholesterolemia; LDLR; PCSK9; Pathogenic variantsCholesterolPhenotypeItalyAutosomal Recessive HypercholesterolemiaApolipoprotein B-100lipids (amino acids peptides and proteins)Proprotein Convertase 9APOBCardiology and Cardiovascular MedicinePreliminary DataGenetic MarkersFamilial hypercholesterolemiaLDLRPCSK9APOBPathogenic variantsHeterozygoteFamilial hypercholesterolemiaBiologyPathogenic variantLDLHyperlipoproteinemia Type II03 medical and health sciencesDatabasesmedicineInternal MedicineHumansAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Internal Medicine; Cardiology and Cardiovascular MedicineGenetic Predisposition to DiseaseFactualPCSK9Settore MED/13 - ENDOCRINOLOGIAAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Cardiology and Cardiovascular Medicine; Internal Medicinemedicine.diseaseAtherosclerosis030104 developmental biologyLDLRReceptors LDLMutationbiology.proteinAPOB; Familial hypercholesterolemia; LDLR; Pathogenic variants; PCSK9; Apolipoprotein B-100; Atherosclerosis; Cholesterol; DNA Mutational Analysis; Databases Factual; Genetic Markers; Genetic Predisposition to Disease; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Italy; Phenotype; Preliminary Data; Prognosis; Proprotein Convertase 9; Receptors LDL; Risk Factors; Mutation; Internal Medicine; Cardiology and Cardiovascular Medicine
researchProduct

Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.

2017

The neurofibromatosis type 2 (NF2) tumor suppressor protein Merlin functions as a negative regulator of cell growth and actin dynamics in different cell types amongst which Schwann cells have been extensively studied. In contrast, the presence and the role of Merlin in oligodendrocytes, the myelin forming cells within the CNS, have not been elucidated. In this work, we demonstrate that Merlin immunoreactivity was broadly distributed in the white matter throughout the central nervous system. Following Merlin expression during development in the cerebellum, Merlin could be detected in the cerebellar white matter tract at early postnatal stages as shown by its co-localization with Olig2-positi…

0301 basic medicineCentral Nervous SystemCytoplasmlcsh:MedicineNervous SystemMyelinMiceCell MovementAnimal CellsCerebellumMedicine and Health SciencesNeurofibromatosis type 2lcsh:ScienceNeuronsStainingCerebral CortexNeurofibromin 2MultidisciplinarybiologyCell StainingBrainCell migrationCell biologyOligodendrogliamedicine.anatomical_structureGenetic DiseasesCell ProcessesAnatomyCellular TypesCellular Structures and OrganellesResearch ArticleCell typeNeurofibromatosis 2NeurogenesisNerve Tissue ProteinsTransfectionResearch and Analysis MethodsCell Line03 medical and health sciencesmedicineAnimalsImmunohistochemistry TechniquesCell ProliferationCell NucleusClinical GeneticsCell growthAutosomal Dominant Diseaseslcsh:RBiology and Life SciencesCell Biologymedicine.diseaseOligodendrocyteMyelin basic proteinMerlin (protein)Mice Inbred C57BLHistochemistry and Cytochemistry Techniques030104 developmental biologySpecimen Preparation and TreatmentAstrocytesNeurofibromatosis Type 2Cellular Neurosciencebiology.proteinImmunologic Techniqueslcsh:QSchwann CellsNeurosciencePLoS ONE
researchProduct

Characterization of the Clinical and Immunologic Phenotype and Management of 157 Individuals with 56 Distinct Heterozygous NFKB1 Mutations

2020

Contains fulltext : 229571.pdf (Publisher’s version ) (Closed access) BACKGROUND: An increasing number of NFKB1 variants are being identified in patients with heterogeneous immunologic phenotypes. OBJECTIVE: To characterize the clinical and cellular phenotype as well as the management of patients with heterozygous NFKB1 mutations. METHODS: In a worldwide collaborative effort, we evaluated 231 individuals harboring 105 distinct heterozygous NFKB1 variants. To provide evidence for pathogenicity, each variant was assessed in silico; in addition, 32 variants were assessed by functional in vitro testing of nuclear factor of kappa light polypeptide gene enhancer in B cells (NF-κB) signaling. RESU…

0301 basic medicineMaleNF-KAPPA-BMedizinlnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4]Fluorescent Antibody TechniqueAutoimmunityDiseaseNUCLEAR-FACTORKaplan-Meier Estimatemedicine.disease_causeHypogammaglobulinemia0302 clinical medicineNFKB1 variants and mutations; autosomal dominant inheritance; common variable immunodeficiency; reduced penetrance; variable expressivityHDE PEDImmunology and Allergyvariants and mutationsNF-κB1-related phenotypeImmunodeficiencyIMMUNODEFICIENCY*NF-?B1-related phenotypeNFKB1 variants and mutations1184 Genetics developmental biology physiologycommon variable immunodeficiencyDisease ManagementMiddle AgedNF-kappa B1-related phenotypereduced penetrancePrognosisPenetranceImmunohistochemistryMagnetic Resonance Imaging3. Good healthPhenotypeNFKB1 variant*NFKB1 variant*common variable immunodeficiencyFemaleHaploinsufficiency*reduced penetranceNFKB1 mutationAdultHeterozygote*NFKB1 mutationImmunologyHAPLOINSUFFICIENCYArticle03 medical and health sciencesvariable expressivityautosomal dominantmedicineHumansGenetic Predisposition to DiseaseGenetic Association StudiesAgedbusiness.industryCommon variable immunodeficiencyNF-kappa B p50 SubunitNF-KAPPA-B1Immune dysregulationmedicine.diseaseautosomal dominant inheritance030104 developmental biologyBiological Variation PopulationImmunologyCELLSMutation*autosomal dominantPrimary immunodeficiency3111 BiomedicinebusinessTomography X-Ray ComputedBiomarkers030215 immunology
researchProduct

One NF1 Mutation may Conceal Another

2019

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease with complete penetrance but high variable expressivity. NF1 is caused by loss-of-function mutations in the NF1 gene, a negative regulator of the RAS-MAPK pathway. The NF1 gene has one of the highest mutation rates in human disorders, which may explain the outbreak of independent de novo variants in the same family. Here, we report the co-occurrence of pathogenic variants in the NF1 and SPRED1 genes in six families with NF1 and Legius syndrome, using next-generation sequencing. In five of these families, we observed the co-occurrence of two independent NF1 variants. All NF1 variants were classified as pathogenic, according to t…

0301 basic medicineMutation ratemedicine.medical_specialtySPRED1congenital hereditary and neonatal diseases and abnormalities<i>SPRED1</i>lcsh:QH426-470[SDV]Life Sciences [q-bio]030105 genetics & heredityBiologyneurofibromatosis type 103 medical and health sciencesGeneticsmedicineNeurofibromatosisneoplasmsGenetics (clinical)Legius syndromeGeneticsMolecular pathologyAutosomal dominant traitmedicine.diseasePenetrance<i>NF1</i>eye diseases3. Good healthnervous system diseases[SDV] Life Sciences [q-bio]Legius syndromelcsh:Genetics030104 developmental biologyNF1Medical geneticsSPRED1 Genede novo variantGenes
researchProduct

European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care

2018

Autosomal dominant polycystic kidney disease (ADPKD) is a chronic, progressive condition characterized by the development and growth of cysts in the kidneys and other organs and by additional systemic manifestations. Individuals with ADPKD should have access to lifelong, multidisciplinary, specialist and patient-centred care involving: (i) a holistic and comprehensive assessment of the manifestations, complications, prognosis and impact of the disease (in physical, psychological and social terms) on the patient and their family; (ii) access to treatment to relieve symptoms, manage complications, preserve kidney function, lower the risk of cardiovascular disease and maintain quality of life;…

2747 Transplantation030232 urology & nephrologyAutosomal dominant polycystic kidney diseaseINTRACRANIAL ANEURYSMS610 Medicine & healthBLOOD-PRESSUREDiseaseClinical practiceGUIDELINES10052 Institute of Physiology03 medical and health sciencesAll institutes and research themes of the Radboud University Medical Center0302 clinical medicineQuality of life (healthcare)NursingQUALITY-OF-LIFEPolycystic kidney diseaseMultidisciplinary approachHealth caremedicinePolycystic kidney diseaseCKDMultispecialist care030212 general & internal medicineDisease management (health)ADPKDOUTCOMESTransplantation2727 NephrologyScience & Technologypolycystic kidney diseasebusiness.industryRENAL REPLACEMENT THERAPYPATIENT PERSPECTIVESUrology & Nephrologymedicine.diseasePREVALENCEclinical practiceTransplantationRenal disorders Radboud Institute for Molecular Life Sciences [Radboudumc 11]CLINICAL-PRACTICENephrologymultispecialist care570 Life sciences; biologybusinessLife Sciences & Biomedicine
researchProduct

HETEROGENITY OF AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA IN SICILY

2004

AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIAMUTATIONSEPIDEMIOLOGY
researchProduct

Hereditary angioedema with a mutation in the plasminogen gene

2017

Background Hereditary angioedema (HAE) with normal C1-INH (HAEnCI) may be linked to specific mutations in the coagulation factor 12 (FXII) gene (HAE-FXII) or functional mutations in other genes that are still unknown. We sought to identify and characterize a hitherto unknown type of HAE with normal C1-INH and without mutation in the F12 gene. Methods The study comprised analysis of whole-exome sequencing, Sanger sequencing, and clinical data of patients. Results We detected a mutation in the plasminogen (PLG) gene in patients with HAEnCI. The mutation c.9886A>G was located in exon 9 leading to the missense mutation p.Lys330Glu (K330E) in the kringle 3 domain of the PLG protein. The mutation…

AdultMale0301 basic medicinePathologymedicine.medical_specialtyAdolescentImmunologyMutation MissenseGene mutationBiologyYoung Adult03 medical and health sciencesExonsymbols.namesake0302 clinical medicineGermanyExome SequencingmedicineHumansImmunology and AllergyMissense mutationChildExome sequencingAgedSanger sequencingAngioedemas HereditaryAutosomal dominant traitPlasminogenMiddle Agedmedicine.disease030104 developmental biology030228 respiratory systemChild PreschoolMutationMutation (genetic algorithm)Hereditary angioedemasymbolsFemaleAllergy
researchProduct

A constitutive BCL2 down-regulation aggravates the phenotype of PKD1-mutant-induced polycystic kidney disease

2017

IF 5.340; International audience; The main identified function of BCL2 protein is to prevent cell death by apoptosis. Mice knock-out for Bcl2 demonstrate growth retardation, severe polycystic kidney disease (PKD), gray hair and lymphopenia, and die prematurely after birth. Here, we report a 40-year-old male referred to for abdominal and thoracic aortic dissection with associated aortic root aneurysm, PKD, lymphocytopenia with a history of T cell lymphoblastic lymphoma, white hair since the age of 20, and learning difficulties. PKD, which was also detected in the father and sister, was related to an inherited PKD1 mutation. The combination of PKD with gray hair and lymphocytopenia was also r…

AdultMale0301 basic medicineTRPP Cation Channelsphenotypebcl2 geneBiologymicro rnaMice03 medical and health sciencesdown-regulationsymptom aggravating factorshemic and lymphatic diseasest-lymphocyteGene expressionGeneticsmedicinePolycystic kidney diseaseAnimalsHumansGenetic Predisposition to Disease[ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human geneticsgenesMolecular BiologyGeneGenetics (clinical)Exome sequencingMice KnockoutPKD1apoptosisExonsGeneral MedicinePolycystic Kidney Autosomal Dominantmedicine.diseasePhenotypePedigreeUp-Regulation3. Good healthMicroRNAs030104 developmental biologyMRNA SequencingProto-Oncogene Proteins c-bcl-2[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsImmunologyCancer researchLymphocytopeniapolycystic kidney diseasesbcl-2 proteinHuman Molecular Genetics
researchProduct

New syndrome: Autosomal dominant microcephaly and radio-ulnar synostosis

1994

To date, the combination of microcephaly and radio-ulnar synostosis has not been recognized as a distinct clinical and genetic entity. We report on 4 familial cases with this previously undescribed combination of defects, showing autosomal dominant inheritance (Fig. 1). © 1994 Wiley-Liss, Inc.

AdultMaleMicrocephalyAdolescentUlnaSupinationMedicineHumansAbnormalities MultiplemicrocephalyChildGenetics (clinical)Genes Dominantradioulnar synostosisbusiness.industryfungiInfantAnatomySyndromeSynostosisMiddle Agedmedicine.diseasePedigreeautosomal dominant inheritanceRadiusSynostosisRadioulnar synostosisFemaleCongenital diseasebusinessHand Deformities Congenital
researchProduct